Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
- Novartis and Eli Lilly oppose a Kerala High Court petition seeking government intervention to lower breast cancer drug prices
- The headline cites prices of Rs 78,400 and Rs 7,750; the summary gives no further details
- Any price intervention could affect Novartis India and Indian pharma companies selling cancer treatments